Search Results for "data"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for data. Results 571 to 580 of 1106 total matches.

Sinemet CR For Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Oct 04, 1991  (Issue 854)
to Average Wholesale Price listings in First DataBank PriceAlert, September 15, 1991 CONCLUSION — Sinemet CR ...
Controlled-release carbidopa/levodopa (Sinemet CR - Dupont Pharma) was recently approved by the US Food and Drug Administration for treatment of Parkinson's disease. The new formulation of this old combination (Sinemet) has the drugs suspended in a polymeric matrix that erodes slowly in the gastrointestinal tract.
Med Lett Drugs Ther. 1991 Oct 4;33(854):92-3 |  Show IntroductionHide Introduction

Lasers Treatment of Cutaneous Vascular Abnormalities

   
The Medical Letter on Drugs and Therapeutics • Nov 01, 1991  (Issue 856)
). Preliminary data suggest that strawberry (capillary) hemangiomas that need treatment respond well ...
In recent years, the availability of new types of lasers has improved the treatment of disfiguring cutaneous vascular abnormalities. Vascular lesions of the skin that can be treated with lasers include port-wine stains, telangiectases, and strawberry hemangiomas (RA Silverman, Pediatr Clin North Am, 38:811, Aug 1991).
Med Lett Drugs Ther. 1991 Nov 1;33(856):104-6 |  Show IntroductionHide Introduction

Tacrolimus FK506 Organ Transplants

   
The Medical Letter on Drugs and Therapeutics • Sep 16, 1994  (Issue 931)
, 25:679, 1993). KIDNEY TRANSPLANTS — Data on the effectiveness of tacrolimus in kidney transplants ...
Tacrolimus (Prograf - Fujisawa), previously called FK506 (Medical Letter, 33:94, 1991), has been approved by the US Food and Drug Administration for primary prevention of organ rejection in patients receiving liver transplants. The drug has also been used as rescue therapy for organ graft rejection unresponsive to cyclosporine (Sandimmune) and other immunosuppressive drugs.
Med Lett Drugs Ther. 1994 Sep 16;36(931):82-3 |  Show IntroductionHide Introduction

Fluvoxamine for Obsessive-Compulsive Disorder

   
The Medical Letter on Drugs and Therapeutics • Feb 17, 1995  (Issue 942)
DataBank PriceAlert January 15, 1995 CONCLUSION — Fluvoxamine can be effective for treatment of obsessive ...
Fluvoxamine (Luvox - Solvay), a selective serotonin reuptake inhibitor (SSRI), has been approved for treatment of obsessive-compulsive disorder (OCD) by the US Food and Drug Administration. Fluoxetine (Prozac), another SSRI antidepressant, and clomipramine (Anafranil), a tricyclic antidepressant that also inhibits serotonin reuptake, are the only other drugs available for this indication in the USA. Antidepressants that do not inhibit serotonin reuptake have not been effective for treatment of this condition.
Med Lett Drugs Ther. 1995 Feb 17;37(942):13-4 |  Show IntroductionHide Introduction

Intravenous, Amiodarone

   
The Medical Letter on Drugs and Therapeutics • Dec 08, 1995  (Issue 963)
agents, even though some data suggest that oral amiodarone may be superior to older drugs ...
An intravenous formulation of amiodarone (Cordarone IV -Wyeth-Ayerst) has been approved by the US Food and Drug Administration (FDA) for treatment and prophylaxis of recurrent ventricular fibrillation (VF) or hemodynamically unstable ventricular tachycardia (VT) in patients refractory to other therapy.
Med Lett Drugs Ther. 1995 Dec 8;37(963):114-5 |  Show IntroductionHide Introduction

Fexofenadine

   
The Medical Letter on Drugs and Therapeutics • Oct 25, 1996  (Issue 986)
interval or, apparently, other adverse effects. CONCLUSION — Although published data are limited ...
Fexofenadine (fex oh fen' a deen) hydrochloride (Allegra - Hoechst Marion Roussel) has been approved by the US Food and Drug Administration for treatment of seasonal allergic rhinitis. An active metabolite of terfenadine, fexofenadine is being heavily advertised as "nonsedating...without 'black box' warnings."
Med Lett Drugs Ther. 1996 Oct 25;38(986):95-6 |  Show IntroductionHide Introduction

Sildenafil: An Oral Drug for Impotence

   
The Medical Letter on Drugs and Therapeutics • May 08, 1998  (Issue 1026)
tablets of any size, according to First DataBank PriceAlert, April 15, 1998. CONCLUSION — Sildenafil ...
Sildenafil citrate (Viagra - Pfizer) is the first oral drug approved by the FDA for treatment of erectile dysfunction. Alprostadil is also marketed for this indication but must be injected into the corpus cavemosum (Caverject) or pushed into the urethra (MUSE).
Med Lett Drugs Ther. 1998 May 8;40(1026):51-2 |  Show IntroductionHide Introduction

Fenofibrate for Hypertriglyceridemia

   
The Medical Letter on Drugs and Therapeutics • Jul 03, 1998  (Issue 1030)
No data are available on the effects of fenofibrate on morbidity and mortality from coronary heart ...
Micronized fenofibrate (Tricor - Abbott), a fibric acid derivative structurally similar to clofibrate (Atromid-S, and others) and gemfibrozil (Lopid, and others), has been approved by the FDA for treatment of hypertriglyceridemia. Increased serum triglyceride concentrations have been associated with an increased risk of coronary heart disease (J Jeppesen et al, Circulation, 97:1029, 1998).
Med Lett Drugs Ther. 1998 Jul 3;40(1030):68-9 |  Show IntroductionHide Introduction

Interferon Plus Ribavirin for Chronic Hepatitis C

   
The Medical Letter on Drugs and Therapeutics • Jun 04, 1999  (Issue 1054)
), but more data are needed. ADVERSE EFFECTS — More than 50% of patients treated with interferon alone ...
Rebetron, a combination of injected recombinant interferon alfa-2b with oral ribavirin has been approved by the FDA for treatment of chronic hepatitis C virus infection.
Med Lett Drugs Ther. 1999 Jun 4;41(1054):53-4 |  Show IntroductionHide Introduction

Rivastigmine (Exelon) For Alzheimer's Disease

   
The Medical Letter on Drugs and Therapeutics • Oct 02, 2000  (Issue 1089)
). In an open-label extension, scores remained high for about 40 weeks before declining, according to data ...
Rivastigmine tartrate (Exelon - Novartis), a carbamate-based cholinesterase inhibitor, is now being marketed for treatment of patients with dementia due to Alzheimer's disease.
Med Lett Drugs Ther. 2000 Oct 2;42(1089):93-4 |  Show IntroductionHide Introduction